Woodline Partners LP Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Woodline Partners LP acquired a new stake in Amylyx Pharmaceuticals, adding approximately $5.70 million, owning about 1.81% of the company by the end of the reporting period.
• Amylyx Pharmaceuticals' stock has seen significant institutional interest, with several firms, including Adage Capital Partners and Millennium Management, increasing their holdings by large percentages.
• The latest earnings report showed a loss of ($0.46) EPS, slightly below expectations, leading analysts to project a full-year EPS of -2.2.

Woodline Partners LP acquired a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,609,447 shares of the company's stock, valued at approximately $5,697,000. Woodline Partners LP owned 1.81% of Amylyx Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter valued at approximately $35,000. Alpine Global Management LLC bought a new stake in Amylyx Pharmaceuticals during the 4th quarter worth approximately $45,000. R Squared Ltd lifted its holdings in Amylyx Pharmaceuticals by 99.9% during the 1st quarter. R Squared Ltd now owns 12,736 shares of the company's stock worth $45,000 after buying an additional 6,366 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in Amylyx Pharmaceuticals by 24.7% during the 1st quarter. Hsbc Holdings PLC now owns 14,419 shares of the company's stock worth $51,000 after buying an additional 2,853 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Amylyx Pharmaceuticals by 18.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company's stock worth $61,000 after buying an additional 2,653 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AMLX has been the topic of a number of analyst reports. Bank of America increased their price target on Amylyx Pharmaceuticals from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Wall Street Zen raised Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, July 18th. The Goldman Sachs Group raised Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 price target on the stock in a research note on Thursday, July 10th. Citigroup assumed coverage on Amylyx Pharmaceuticals in a research note on Tuesday, June 17th. They issued a "buy" rating and a $12.00 price target on the stock. Finally, Guggenheim raised their price objective on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $13.25.

Amylyx Pharmaceuticals Price Performance

AMLX stock traded up $0.20 during trading hours on Monday, reaching $11.85. 1,926,689 shares of the stock were exchanged, compared to its average volume of 1,827,795. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -4.74 and a beta of -0.45. The firm's 50-day moving average is $8.74 and its 200-day moving average is $6.07. Amylyx Pharmaceuticals, Inc. has a 12 month low of $2.59 and a 12 month high of $12.25.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.02). As a group, equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.